자동 세포배양 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 용도별, 최종사용자별, 지역별 및 부문별 예측(2026-2033년)

Automated Cell Culture Market Summary

The global automated cell culture market size was estimated at USD 21.4 billion in 2025 and is projected to reach USD 56.1 billion by 2033, growing at a CAGR of 13.2% from 2025 to 2033. The market growth is driven by rising demand for scalable, reproducible cell-based processes and increasing adoption of automation, supported by advancements in robotics and AI.

Expansion of Biologics & Cell/Gene Therapy Pipelines

The rapid expansion of biologics and advanced therapy pipelines, particularly monoclonal antibodies, vaccines, and cell and gene therapies, is a key driver for the automated cell culture industry. Biopharmaceutical companies are increasingly focusing on complex, cell-based products that require controlled and reproducible culture conditions. At the same time, the growing number of cell and gene therapy candidates in clinical development is driving demand for precise cell expansion and maintenance, which is difficult to achieve through manual processes.

As a result, automated cell culture systems are becoming essential for ensuring scalability, consistency, and process standardization. These platforms reduce variability, enable controlled environments, and support both small-batch personalized production and large-scale manufacturing. This is especially critical for patient-specific therapies, where accuracy and traceability are vital, thereby accelerating the adoption of automation in cell culture market.

Global Automated Cell Culture Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the automated cell culture market report based on product type, application, end user, and region:

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Consumables
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug development
• Biopharmaceutical production
• Cell & gene therapy manufacturing
• Tissue Culture & Engineering
• Toxicity Testing
• Other Applications
• End User Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & biotech companies
• Academic & research institutes
• Hospitals & diagnostic labs
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• MEA
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product Type Segment
  • 1.2.2. Application Segment
  • 1.2.3. End User Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Automated Cell Culture Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Expansion of biologics & cell/gene therapy pipelines
    • 3.2.1.2. Reduction of variability & human error
    • 3.2.1.3. Advancements in robotics, AI, and real-time monitoring technologies
    • 3.2.1.4. Shift toward closed-system and GMP-compliant workflows
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High initial capital investment and operating costs
    • 3.2.2.2. Complexity in system integration and workflow standardization
  • 3.2.3. Market opportunity analysis
  • 3.2.4. Market challenge analysis
• 3.3. Case Study Insights
• 3.4. Automated Cell Culture Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
  • 3.4.2. PESTEL Analysis

Chapter 4. Automated Cell Culture Market: Product Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Automated Cell Culture Market Product Type Movement Analysis
• 4.3. Global Automated Cell Culture Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
• 4.4. Instruments
  • 4.4.1. Instruments market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Consumables
  • 4.5.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Automated Cell Culture Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Automated Cell Culture Market Application Movement Analysis
• 5.3. Global Automated Cell Culture Materials Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Drug development
  • 5.4.1. Drug development market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Biopharmaceutical production
  • 5.5.1. Biopharmaceutical production market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Cell & gene therapy manufacturing
  • 5.6.1. Cell & gene therapy manufacturing market estimates and forecasts 2021 to 2033 (USD Million)
• 5.7. Tissue Culture & Engineering
  • 5.7.1. Tissue Culture & Engineering market estimates and forecasts 2021 to 2033 (USD Million)
• 5.8. Toxicity Testing
  • 5.8.1. Toxicity Testing market estimates and forecasts 2021 to 2033 (USD Million)
• 5.9. Other Applications
  • 5.9.1. Other Applications market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Automated Cell Culture Market: End User Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Automated Cell Culture Market End User Movement Analysis
• 6.3. Global Automated Cell Culture Market Size & Trend Analysis, by End User, 2021 to 2033 (USD Million)
• 6.4. Pharmaceutical & biotech companies
  • 6.4.1. Pharmaceutical & biotech companies market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Academic & research institutes
  • 6.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Hospitals & diagnostic labs
  • 6.6.1. Hospitals & diagnostic labs market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Automated Cell Culture Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033
• 7.4. North America
  • 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 7.5. Europe
  • 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key country dynamics
    • 7.5.8.2. Competitive scenario
    • 7.5.8.3. Regulatory framework
    • 7.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.9. Denmark
    • 7.5.9.1. Key country dynamics
    • 7.5.9.2. Competitive scenario
    • 7.5.9.3. Regulatory framework
    • 7.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Latin America
  • 7.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. MEA
  • 7.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2025
• 8.4. Company Profiles/Listing
  • 8.4.1. Thermo Fisher Scientific, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Danaher Corporation
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Sartorius AG
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Merck KGaA
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Lonza Group
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Becton, Dickinson and Company (BD)
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Corning Incorporated
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Eppendorf SE
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Tecan Group
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Agilent Technologies
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives